中华生物医学工程杂志
中華生物醫學工程雜誌
중화생물의학공정잡지
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
2013年
3期
230-232
,共3页
鲁建军%翁慧雯%顾勇%罗红鹤%钟佛添
魯建軍%翁慧雯%顧勇%囉紅鶴%鐘彿添
로건군%옹혜문%고용%라홍학%종불첨
核糖核酸Ⅱ%胸腔积液,恶性%化学疗法,癌,局部灌注%T淋巴细胞亚群
覈糖覈痠Ⅱ%胸腔積液,噁性%化學療法,癌,跼部灌註%T淋巴細胞亞群
핵당핵산Ⅱ%흉강적액,악성%화학요법,암,국부관주%T림파세포아군
Ribonucleic acid Ⅱ%Pleural effusion,malignant%Chemotherapy,cancer,regional perfusion%T-lymphocyte subsets
目的 观察注射用核糖核酸Ⅱ胸内注入治疗恶性胸腔积液的疗效及其对机体免疫功能的影响.方法 收集2012年3月至2013年2月本院经病理和(或)细胞学确诊的晚期肺部肿瘤所至的恶性胸腔积液的患者63例,经胸腔穿刺抽液或胸腔闭式引流后即时注入注射用核糖核酸Ⅱ300 mg,治疗1周胸部X线显示如仍有胸腔积液再引流后重复给药1次.4周后按WHO规定的临床疗效评定标准,观察注射用核糖核酸Ⅱ的恶性胸腔积液控制疗效,并应用流式细胞仪对比治疗前后(注药前和注药后1周)患者外周血T淋巴细胞的变化情况.结果 注射用核糖核酸Ⅱ胸腔内注入疗法的总体有效率达90.48％,其中完全缓解(CR)30例(47.62％),部分缓解(PR)14例(22.22％),稳定(SR)13例(20.63％),无效6例.治疗后外周血T淋巴细胞亚群中的CD3+、CD4+水平和CD4+/CD8+值较治疗前升高(CD3+:67.49±6.41比64.21±4.87,CD4+:28.72±3.85比24.59±3.47,CD4+/CD8+:0.91±0.07比0.65±0.04,均P＜0.05),CD8+水平明显下降(33.96±5.86比38.16±4.89,P＜0.05).结论 注射用核糖核酸Ⅱ胸腔内注入疗法治疗恶性胸腔积液的疗效确切,能明显改善机体状况和增强免疫功能.
目的 觀察註射用覈糖覈痠Ⅱ胸內註入治療噁性胸腔積液的療效及其對機體免疫功能的影響.方法 收集2012年3月至2013年2月本院經病理和(或)細胞學確診的晚期肺部腫瘤所至的噁性胸腔積液的患者63例,經胸腔穿刺抽液或胸腔閉式引流後即時註入註射用覈糖覈痠Ⅱ300 mg,治療1週胸部X線顯示如仍有胸腔積液再引流後重複給藥1次.4週後按WHO規定的臨床療效評定標準,觀察註射用覈糖覈痠Ⅱ的噁性胸腔積液控製療效,併應用流式細胞儀對比治療前後(註藥前和註藥後1週)患者外週血T淋巴細胞的變化情況.結果 註射用覈糖覈痠Ⅱ胸腔內註入療法的總體有效率達90.48％,其中完全緩解(CR)30例(47.62％),部分緩解(PR)14例(22.22％),穩定(SR)13例(20.63％),無效6例.治療後外週血T淋巴細胞亞群中的CD3+、CD4+水平和CD4+/CD8+值較治療前升高(CD3+:67.49±6.41比64.21±4.87,CD4+:28.72±3.85比24.59±3.47,CD4+/CD8+:0.91±0.07比0.65±0.04,均P＜0.05),CD8+水平明顯下降(33.96±5.86比38.16±4.89,P＜0.05).結論 註射用覈糖覈痠Ⅱ胸腔內註入療法治療噁性胸腔積液的療效確切,能明顯改善機體狀況和增彊免疫功能.
목적 관찰주사용핵당핵산Ⅱ흉내주입치료악성흉강적액적료효급기대궤체면역공능적영향.방법 수집2012년3월지2013년2월본원경병리화(혹)세포학학진적만기폐부종류소지적악성흉강적액적환자63례,경흉강천자추액혹흉강폐식인류후즉시주입주사용핵당핵산Ⅱ300 mg,치료1주흉부X선현시여잉유흉강적액재인류후중복급약1차.4주후안WHO규정적림상료효평정표준,관찰주사용핵당핵산Ⅱ적악성흉강적액공제료효,병응용류식세포의대비치료전후(주약전화주약후1주)환자외주혈T림파세포적변화정황.결과 주사용핵당핵산Ⅱ흉강내주입요법적총체유효솔체90.48％,기중완전완해(CR)30례(47.62％),부분완해(PR)14례(22.22％),은정(SR)13례(20.63％),무효6례.치료후외주혈T림파세포아군중적CD3+、CD4+수평화CD4+/CD8+치교치료전승고(CD3+:67.49±6.41비64.21±4.87,CD4+:28.72±3.85비24.59±3.47,CD4+/CD8+:0.91±0.07비0.65±0.04,균P＜0.05),CD8+수평명현하강(33.96±5.86비38.16±4.89,P＜0.05).결론 주사용핵당핵산Ⅱ흉강내주입요법치료악성흉강적액적료효학절,능명현개선궤체상황화증강면역공능.
Objective To determine the efficacy of ribonucleic acid Ⅱ (RNA Ⅱ) intrathoracic injection on malignant pleural effusion and the host immunity.Methods Sixty-three patients with pathologyand (or) cytology-diagnosed malignant pleural effusion admitted to The First Affiliated Hospital,Sun Yatsen University between March 2012 and February 2013 were subjected to RNA Ⅱ (300 mg,once weekly) injection via thoracocentesis or thoracic cavity closed drainage.Repetitive administration was performed in case of pleural effusion as suggested by chest X-ray at week 1.The therapeutic outcomes were assessed based on the WHO criteria.The changes in peripheral blood T cells was assessed using flow cytometry prior to and following one week after the treatment.Results The RNA Ⅱ intrathoracic injection yielded an overall effective rate of 90.48％,consisting of 30 cases with complete remission (CR,47.62％),14 partial remission (PR,22.22％),13 stability rate (SR,20.63％) and 6 inefficiency.Treatment with RNA Ⅱ resulted in significantly increased levels of CD3+ (67.49±6.41 vs 64.21±4.87,P＜0.05),CD4+ cells (28.72± 3.85 vs 24.59±3.47,P＜0.05) and CD4+/CD8+ ratio (0.91±0.07 vs 0.65±0.04,P＜0.05),yet markedly reduced CD8+ cells (33.96±5.86 vs 38.16±4.89,P＜0.05).Conclusion RNA Ⅱ intrathoracic injection has definite efficacy on malignant pleural effusion and can improve physical conditions and host immunity.
